Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can PET-CT scans better predict breast cancer treatment success?

NCT ID NCT07173868

Knowledge-focused Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study is testing whether a special type of PET-CT scan (F-18 FDG PET-CT) can better track how well treatment is working in people with advanced breast cancer compared to standard imaging like CT scans. Researchers will follow 100 patients for 48 weeks after they start their first systemic therapy. The goal is to see if the PET-CT scan gives a clearer picture of treatment response, which could help doctors make better decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
F-18 FDG PET-CT imaging
What this could lead to
If successful, this could show that PET-CT scans are better than standard imaging at predicting outcomes, potentially guiding more personalized treatment decisions.
What could go wrong
This is an observational study with only 100 participants, so results may not apply to all patients. It compares imaging methods, not treatments, so it won't directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Histologically confirmed metastatic or locally advanced breast cancer patients with no radical topical treatment

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 19 years of age or older 2. histologically confirmed metastatic or locally advanced breast cancer with no radical topical treatment available 3. If there is liver metastasis, which the researcher believes will be difficult to evaluate the response accurately with bone metastasis or CT 4. May or may not have measurable lesions in accordance with RECIST 1.1 criteria 5. Patients who meet the criteria for coverage of F-18 FDG PET-CT tests conducted for the purpose of evaluating treatment response according to the Health Insurance Review and Assessment Service's announcement 6. Patients scheduled to start primary systemic therapy for advanced breast cancer (endocrine therapy, targeted therapy, chemotherapy, immunotherapy or their combination therapy) 7. Patients willing to undergo continuous response assessments using F-18 FDG PET-CT and CE-CT (± bone scan if clinically necessary) at the time point specified in the study plan (before treatment, 6, 12, 24, 48 weeks after treatment) and willing to pay for the examination accordingly 8. ECOG Performance Status 0-2 Exclusion Criteria: 1. a patient who has previously received systemic treatment for advanced breast cancer 2. Taboos for F-18 FDG PET-CT (e.g., uncontrolled diabetes) or intravenous contrast agents for CE-CT (e.g., severe allergies, severe renal dysfunction) 3. Pregnancy or lactation 4. At the same time, other primary malignancies (except when treatment has been completed for radical purposes) are known 5. Other medical conditions that, at the discretion of the researcher, may hinder participation in the study or affect the interpretation of the results 6. If you are unable to follow a research procedure or follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Histologically confirmed metastatic or locally advanced breast cancer with no radical topical treatment available If there is liver metastasis, which the researcher believes will be difficult to evaluate the response accurately with bone metastasis or CT

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Samsung medical Center

    RECRUITING

    Seoul, Gannam-gu, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.